[작성자:] cms3billion
-

CNV 분석! 엑솜으로 가능한가요?
희귀질환이 의심되는 환자를 만나면, 가장 먼저 어떤 검사를 떠올리시나요? 최근 희귀 유전질환의 일상적인 진단 도구로 엑솜 검사가 많이 쓰이고 있지만, 여전히 많은 의료진은 CMA(Chromosomal Microarray)를 가장 먼저 선택합니다. 실제로, 유전자 내 50bp 이상의 deletion/duplication 등 CNV는 상당 수의 유전질환(10~15%)을 유발합니다. CMA는 CNV(Copy number variant) 분석에 가장 일반적으로 쓰이며, 50kb 이상의 CNV를 감지할 수 있습니다. 그러나…
-

AI in Genetic Testing: How 3billion is Revolutionizing Rare Disease Diagnosis
AI is revolutionizing genetic testing by improving accuracy, speed, and accessibility. Companies like 3billion are pioneering the integration of AI in rare disease diagnosis, making genetic testing faster, more affordable, and accessible worldwide. This is precisely the kind of AI-driven transformation I am committed to in my own journey at the intersection of AI and…
-

Rare Disease Diagnosis in the Middle East: How WES and WGS Are Improving Outcomes
Rare diseases affect approximately 300 to 400 million people globally, with an estimated prevalence of 6% to 8% of the population. In the Middle East and North Africa (MENA) region, the burden of rare diseases is significantly higher due to several socio-demographic and genetic factors, including high rates of consanguinity, large family sizes, and limited…
-

3billion Partners with Seoul Asan Medical Center to Support Genetic Testing for 28 Patients
On February 28, 2025, in celebration of Rare Disease Day, 3billion held a 228km marathon challenge to raise awareness and support for rare disease patients. Over 30 employees participated, collectively covering the distance and successfully securing funds to provide whole-exome sequencing (WES) tests for 28 patients. The initiative reflects 3billion’s commitment to improving the diagnosis…
-

엑솜 가격, 얼마인가요?
오늘은 가장 많은 분들이 궁금해하시는 엑솜 검사 가격에 대해 이야기 해보려 합니다. 지난 번 글을 보신 분들이라면, “엑솜” 검사에는 2가지 의미가 섞여 있다는 것을 아실텐데요. 쓰리빌리언 엑솜 검사는 2번에 해당하고, 정가는 99만원 입니다. (물론 협상의 단계가 있는거 아시죠 😁) 보통 1번을 기대하고 여쭤보신 분들은 “너무 비싸네요~ 라는 답변을 주시고, 2번을 기대하고 여쭤보신 분들은 “많이 저렴해졌네요”…
-

Women and Rare Diseases: The Critical Role of Genetic Testing
Rare diseases affect millions of people worldwide, with women often bearing a disproportionate burden due to diagnostic delays, gender bias in medical research, and unique genetic susceptibilities. Many rare diseases are genetic in nature, making genetic testing a crucial tool for early diagnosis, treatment planning, and family risk assessment. Understanding the role of genetic testing…